8-K filed May 8, 2026, 7:59 PM ET ticker NKTR CIK 0000906709

other material confidence high sentiment neutral materiality 0.75

Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO

NEKTAR THERAPEUTICS

Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright for up to $150M of common stock in at-the-market offerings.
Sandra Gardiner retiring as interim CFO effective May 15, 2026; Linda Rubinstein of FLG Partners will succeed her.
Rubinstein has over 35 years experience, raised >$5B in financings, and previously CFO of Adverum Biotechnologies.
Shares may be sold through ordinary brokers' transactions on Nasdaq at market prices; 3.0% commission fee to agents.

item 1.01 item 5.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-214976
form_type: 8-K
ticker: NKTR
cik: 0000906709
company_name: NEKTAR THERAPEUTICS
filed_at: 2026-05-08T23:59:59+00:00
discovered_at: 2026-05-14T18:02:33.914871+00:00
generated_at: 2026-05-14T21:17:49.739425+00:00
sec_items: ["1.01", "5.02", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-214976
json_url: https://secwatch.observer/filing/0001193125-26-214976.json
markdown_url: https://secwatch.observer/filing/0001193125-26-214976.md
text_url: https://secwatch.observer/filing/0001193125-26-214976.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/d159808d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Linda Rubinstein

interim Chief Financial Officer

NKTR · NEKTAR THERAPEUTICS

Effective: 2026-05-15
Filed: May 8, 2026, 7:59 PM ET

Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.

Departed (interim)

Sandra Gardiner

interim Chief Financial Officer

NKTR · NEKTAR THERAPEUTICS

Effective: 2026-05-15
Successor: Linda Rubinstein
Filed: May 8, 2026, 7:59 PM ET

On May 7, 2026, the Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026.

Source-grounded claims

c637163245

Linda Rubinstein was appointed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.

Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

eb697dfc1c

Sandra Gardiner departed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.

On May 7, 2026, the Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

601bef46dca020c84af9e47aeae1c7ade3ca6330

NEKTAR THERAPEUTICS entered into Equity Distribution Agreement with Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC valued at $150,000,000 (effective 2026-05-08).

On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

FDXF

FedEx Freight completes spin-off from FedEx; $600M drawn, new board and executives appointed

FedEx Freight Holding Company, Inc. June 1, 2026, 6:46 AM ET other_material Items 1.01, 2.03, 3.03, 5.03, 5.01, 5.02, 5.05, 8.01, 9.01

same fact type: executive_change same SEC item: 1.01, 5.02, 9.01 same event type: other_material similar materiality

This filing

Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.

Comparable filing

each of John A. Smith, R. Brad Martin, Jeffrey A. Davis, Donald E. Frieson, Stephen E. Gorman, Robert A. King, Cindy J. Miller, Amy J. Salcido, and Samantha M. Smith was appointed to the Board

Filing page SEC filing

FXAC

FortuneX Acquisition closes IPO of 8.625M units at $10/unit, raising $86.25M gross

FortuneX Acquisition Corp May 29, 2026, 5:32 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 9.01

same fact type: executive_change same SEC item: 1.01, 5.02, 9.01 same event type: other_material similar materiality

This filing

Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.

Comparable filing

Effective May 19, 2026, in connection with the effectiveness of the Company’s Registration Statement, Becky Fallon, Sean Michael Deegan, and Robert Labbe became members of the board of directors (the “Board”) of the Company.

Filing page SEC filing

CRMT

America's Car-Mart forms special committee for strategic alternatives; appoints new independent director

AMERICAS CARMART INC May 29, 2026, 5:30 PM ET other_material Items 1.01, 5.02, 8.01, 9.01

same fact type: executive_change same SEC item: 1.01, 5.02, 9.01 same event type: other_material similar materiality

This filing

Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.

Comparable filing

On May 22, 2026, the Board increased the size of the Board from nine members to ten members and appointed Adam Paul as an independent director, effective immediately.

Filing page SEC filing

OHAC

Oceanhawk Acquisition Corp. closes upsized $160M IPO of 16M units at $10/unit

Oceanhawk Acquisition Corp. May 27, 2026, 4:01 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: executive_change same SEC item: 1.01, 5.02, 9.01 same event type: other_material similar materiality

This filing

Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.

Comparable filing

On May 20, 2026, in connection with the IPO, each of Joseph Durnford, Ernest Miller, Jon Ryan, Mike Maggard, Dan Collingridge-Padbury and Jonathan Nickell (collectively, the “ Directors ”) was appointed to the board of directors of the Company (the “ Board ”).

Filing page SEC filing

PUBC

Purebase to receive 20% of net proceeds from CoreTer mining deal; waives corporate opportunities

Purebase Corp June 1, 2026, 3:42 PM ET other_material Items 1.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.

Comparable filing

On May 26, 2026, Purebase Corporation (the “Company”) entered into a binding Memorandum of Understanding (the “MOU”) with CoreTer LLC, a Nevada limited liability company (“CoreTer”), pursuant to which the Company will be entitled to 20% of the net proceeds received by CoreTer under an Exclusive Mining Option and Development Agreement, dated March 19, 2026, between CoreTer and Dexter Mining LLC.

Filing page SEC filing

LIXT

Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board

LIXTE BIOTECHNOLOGY HOLDINGS, INC. June 1, 2026, 8:55 AM ET other_material Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material similar materiality

This filing

Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.

Comparable filing

On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.

Filing page SEC filing

ELOX

Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors

Eloxx Pharmaceuticals, Inc. June 1, 2026, 7:00 AM ET other_material Items 3.02, 3.03, 5.03, 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material similar materiality

This filing

Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.

Comparable filing

the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board

Filing page SEC filing

MVST

Microvast CEO converts $25M loan to equity; CAO Eric Garcia departs

Microvast Holdings, Inc. May 28, 2026, 5:26 PM ET other_material Items 5.02, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: other_material similar materiality

This filing

Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.

Comparable filing

On May 27, 2026, Eric N. Garcia ceased to be employed as Chief Accounting Officer of Microvast Holdings, Inc. (the “Company”).

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-214976

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.